Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Chemical Biology 4, 91–93 (1 February 2008) | doi:10.1038/nchembio0208-91
Losing inhibition with ketamine
Abstract
Schizophrenia is a devastating illness, and efforts at developing treatments have been hampered, in part, by a limited understanding of the molecular basis of the disease. It is known that people with schizophrenia exhibit apparent decreases in glutamatergic N-methyl-D-aspartic acid (NMDA) receptor subunit expression and alterations in signaling pathways downstream of the receptor.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
